Prime Therapeutics的动态

Shield Therapeutics plc CEO Anders Lundstrom and CFO Santosh Shanbhag joined Steve Darling from Proactice to share its released an unaudited Q3 2024 trading update revealing $7.2 million in net revenues from ACCRUFeR prescriptions, with an average net selling price of $167 per prescription. Excluding July's summer buying trends, the NSP averaged $192 in Q3, and Shield anticipates maintaining this level into Q4. Shield looks to gain traction, especially in the United States, where it partners with Viatris, deploying a sales force of 100 to promote ACCRUFeR. To support its objective of achieving cash flow positivity by 2025, Shield has expanded its working capital financing with Sallyport Commercial Finance from $10 million to $15 million. Additionally, Shanbhag also noted that steps are being taken to improve Shield’s cash position, including a planned 10% cost reduction and expanded financing from Sallyport, which he... Watch at #Proactive #ProactiveInvestors https://ow.ly/KFbx105Nh15

Get an inside look at how Prime Therapeutics is reshaping the PBM landscape!

Look at this panel discussion webinar coming up. With experts from the likes of 4c LifeSciences, Kyowa Kirin, ADC Therapeutics, Dragonfly Therapeutics (and of course our very own Anca Copaescu). You will learn about - Importance of category management - Key criteria for vendor onboarding - Vendor evaluation workflows - Risk Management - Latest trends and innovation

For anyone who has vendor management/evaluation in their remit, this webinar is "must see viewing". Great topic + Great Panel = Thought provoking ideas

Get an inside look at how Prime Therapeutics is reshaping the PBM landscape!

Agreed, the patient-centric approach is so important when it comes to treatments.

Watch our webinar with Chimeric Therapeutics, featuring COO Dr. Rebecca McQualter. The webinar will feature an interview and a live Q&A with the audience, providing you the opportunity to ask Rebecca any questions about CHM that you may have. Key topics: - Introduction to the company - The clinic’s 3 assets and how this milestone was achieved - What’s on the pipeline and future value drivers Register: https://hubs.la/Q02BtNpK0 #asx #CHM #stocks

#Slack DMs can make it hard to track requests and measure workload impact of your #ITHelpdesk. Hear how Cohere, Xilio Therapeutics and Foqal took back control in 4/17 webinar https://hubs.ly/Q02pyQ0V0

#Slack DMs can make it hard to track requests and measure workload impact of your #ITHelpdesk. Hear how Cohere, Xilio Therapeutics and Foqal took back control 4/17 webinar https://hubs.li/Q02pyTc90